Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this drugmaker have returned -3% over the past month versus the Zacks S&P 500 composite's +3% change. The Zacks Large Cap Pharmaceuticals industry, to which Pfizer belongs, has gained 6.9% over this period. Now the key question is: Where could the stock be headed in the near term?Although media reports or rum ...

Pfizer (PFE) announced that the European Commission has granted marketing approval to its oral, once-daily pill called Velsipity (etrasimod) to treat moderately to severely active ulcerative colitis (UC).The approval for the oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator (2 mg dose) is for UC patients who are 16 years of age and older and who have had an inadequate response, lost response, or were intolerant to either conventional therapy or injectable therapies like biologics. ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent. “For the 2.6 million people in Europe living with UC, the unpredictable physical, mental, and ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Oncology Innovation Day on Thursday, February 29, 2024, from 1:00 p.m. EST to 5:30 p.m. EST, with an approximately 20-minute break at the midpoint. During the event, Pfizer Oncology leadership will provide details on the new combined Pfizer Oncology Division, including its strategic approach, robust portfolio, industry-leading R&D capabilities and potential for growth through 203 ...

Key PointsPfizer's stock has experienced a significant decline of over 50% from its pandemic peak.Despite challenges, Pfizer's latest earnings report revealed resilience, topping estimates with an unexpected fourth-quarter profit.Analysts forecast an impressive upside for Pfizer, with a consensus price target of $36.93, and the stock boasts an attractive dividend yield of 6.11%.5 stocks we like better than PfizerFor shareholders of the multinational biotech giant Pfizer Inc. NYSE: PFE, it might feel like th ...

Future Publishing/Future Publishing via Getty Images My Thesis In my opinion, Pfizer Inc. (NYSE:PFE) stock is the ultimate buying opportunity for income investors seeking exposure to the healthcare sector. This is due to the depressed valuation of the company, which comes from negative market sentiment surrounding PFE. With Pfizer's product pipeline getting stronger and older drugs continuing to generate good FCF, I believe investors should consider buying PFE for their long-term portfolio today at the curr ...

Bloomberg/Bloomberg via Getty Images 0Pfizer Overview Pfizer Inc. (NYSE:PFE) just celebrated its 175th birthday, and is one of the largest so-called "big pharma" in the world. The company became a household name in recent years due to its COVID vaccine (co-developed with BioNtech (BNTX)) and its COVID drug and how both played a key role in fighting the pandemic. In return Pfizer raked in ~$57 Billion USD in revenue as a result of its two COVID products in 2021 and 2022 alone. Yet since its height of $56.33 ...

Pfizer Inc (NYSE:PFE, ETR:PFE) had some rare good news in a tough 12 months for the US pharma as a new study suggested that men who take Viagra for erectile dysfunction might have a reduced risk of Alzheimer's disease. Research involving over 260,000 men found that those using drugs like Viagra were 18% less likely to develop the condition, researchers from University College London found. Viagra, originally designed for high blood pressure and angina, acts on a cell-signalling messenger potentially linked ...

A lot can change on the stock market in just a few years, and Pfizer (PFE -0.16%) is a great example. At the end of 2021, its shares were trading at around $60, and things were looking great for the COVID-19 vaccine maker. It would go on to hit a record of more than $100 billion in annual revenue in 2022. Today, however, the stock is below $30 per share. What was once hype and excitement surrounding the stock has now been replaced with fear and concern as investors worry about what the future holds for the ...

Michael M. Santiago Pfizer (NYSE:PFE) submitted a better than expected earnings card for the fourth fiscal quarter last week. Despite a drop-off in COVID-19 related product revenues, Pfizer has been able to deliver solid organic top line growth in the fourth quarter as well as FY 2023. The pharmaceutical giant also confirmed its financial outlook and guided for Y/Y revenue upside in FY 2024. In my opinion, the drop-off in Corminaty and Paxlovid sales has created overly negative sentiment overhang for Pfizer ...